Cardiac Hypertrophy: From Pathophysiological Mechanisms to Heart Failure Development

Alfredo Caturano1, Erica Vetrano1, Raffaele Galiero1

  • 1Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", I-80138 Naples, Italy.

Insights

Cardiac hypertrophy, a response to increased heart workload, can lead to heart failure. Understanding its molecular mechanisms is key for developing new therapies to prevent and reverse this condition.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pathophysiology

Background:

  • Cardiac hypertrophy is an adaptive response to increased workload, aiming to reduce ventricular wall stress.
  • Persistent stimuli can cause pathological hypertrophy, leading to heart failure, impaired function, and increased mortality.
  • Diabetic cardiomyopathy involves pathological hypertrophy driven by insulin resistance, hyperglycemia, and associated metabolic and inflammatory changes.

Purpose of the Study:

  • To review the molecular mechanisms underlying pathological cardiac hypertrophy.
  • To explore how these mechanisms contribute to conditions like diabetic cardiomyopathy.
  • To identify potential therapeutic targets for preventing and reversing cardiac hypertrophy.

Main Methods:

  • Literature review of molecular mechanisms in pathological cardiac hypertrophy.
  • Analysis of pathophysiological pathways including cell death, fibrosis, and metabolic alterations.
  • Examination of the role of insulin resistance and hyperglycemia in diabetic cardiomyopathy.

Main Results:

  • Pathological hypertrophy involves complex mechanisms: cell death, fibrosis, mitochondrial dysfunction, altered metabolism, and impaired quality control.
  • Fetal gene reactivation, sarcomere disorganization, and inadequate angiogenesis are key features.
  • Diabetic cardiomyopathy highlights the impact of metabolic dysregulation on cardiac remodeling.

Conclusions:

  • Understanding the molecular basis of pathological hypertrophy is crucial for therapeutic development.
  • Targeting specific pathways could offer novel strategies for treating and preventing heart failure.
  • Interventions may focus on metabolic correction, improving protein/mitochondrial quality, and modulating inflammatory responses.

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
624
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
355
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
332